{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:41:57Z","timestamp":1792226517101,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"DOI":"10.1007\/s00213-026-07187-5","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:05:04Z","timestamp":1792224304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["What goes up must comedown: prevalence rates, characteristics, and coping strategies concerning MDMA aftereffects"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5631-4346","authenticated-orcid":false,"given":"Sean P.","family":"Goldy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelcy A.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Yaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep M.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"7187_CR1","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1097\/00001756-199911260-00039","volume":"10","author":"N Aguirre","year":"1999","unstructured":"Aguirre N, Barrionuevo M, Ram\u00c2\u00f5rez MJ, R\u00c2\u00f5o JD, Lasheras B (1999) \u00c1-Lipoic acid prevents 3,4-methylenedioxy- methamphetamine (MDMA)-induced neurotoxicity. NeuroReport 10:3675\u20133680","journal-title":"NeuroReport"},{"issue":"2","key":"7187_CR2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.neuroscience.2008.10.041","volume":"158","author":"E Alves","year":"2009","unstructured":"Alves E, Binienda Z, Carvalho F, Alves CJ, Fernandes E, Bastos MdeL, Tavares MA, Summavielle T (2009) Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience 158(2):514\u2013523. https:\/\/doi.org\/10.1016\/j.neuroscience.2008.10.041","journal-title":"Neuroscience"},{"key":"7187_CR3","unstructured":"Baggott MJ, Mendelson J (2001) Does MDMA cause brain damage? Ecstasy: The complete guide: A comprehensive look at the risks and benefits of MDMA. Park Street"},{"issue":"3","key":"7187_CR4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","volume":"67","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Ball R, Ranieri W (1996) Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 67(3):588\u2013597. https:\/\/doi.org\/10.1207\/s15327752jpa6703_13","journal-title":"J Pers Assess"},{"key":"7187_CR5","doi-asserted-by":"publisher","first-page":"112881","DOI":"10.1016\/j.drugalcdep.2025.112881","volume":"276","author":"M Blankers","year":"2025","unstructured":"Blankers M, Van Beek R, Spronk D, Den Hollander W, Andree R, Freeman TP, Grabski M, Curran HV, Waldron J, Van Laar MW (2025) Three-day blues after ecstasy\/MDMA use: Evidence from a longitudinal and daily analysis in the European nightlife scene. Drug Alcohol Depend 276:112881. https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112881","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"7187_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0269881120926673","volume":"35","author":"A Borissova","year":"2021","unstructured":"Borissova A, Ferguson B, Wall MB, Morgan CJ, Carhart-Harris RL, Bolstridge M, Bloomfield MA, Williams TM, Feilding A, Murphy K, Tyacke RJ, Erritzoe D, Stewart L, Wolff K, Nutt D, Curran HV, Lawn W (2021) Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. J Psychopharmacol 35(5):547\u2013555. https:\/\/doi.org\/10.1177\/0269881120926673","journal-title":"J Psychopharmacol"},{"key":"7187_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jad.2024.08.091","volume":"365","author":"AE Calder","year":"2024","unstructured":"Calder AE, Hasler G (2024) Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA. J Affect Disord 365:258\u2013264. https:\/\/doi.org\/10.1016\/j.jad.2024.08.091","journal-title":"J Affect Disord"},{"issue":"8","key":"7187_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41386-024-01865-8","volume":"49","author":"J Colcott","year":"2024","unstructured":"Colcott J, Guerin AA, Carter O, Meikle S, Bedi G (2024) Side-effects of mdma-assisted psychotherapy: A systematic review and meta-analysis. Neuropsychopharmacology 49(8):1208\u20131226. https:\/\/doi.org\/10.1038\/s41386-024-01865-8","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"7187_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1360-0443.1997.tb02951.x","volume":"92","author":"HV Curran","year":"1997","unstructured":"Curran HV, Travill RA (1997) Mood and cognitive effects of \u00b1\u20093,4-methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019): Week-end \u2018high\u2019 followed by mid-week low. Addiction 92(7):821\u2013831. https:\/\/doi.org\/10.1111\/j.1360-0443.1997.tb02951.x","journal-title":"Addiction"},{"issue":"4","key":"7187_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/npp.2017.171","volume":"43","author":"MK Doss","year":"2018","unstructured":"Doss MK, Weafer J, Gallo DA, de Wit H (2018) MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections. Neuropsychopharmacology 43(4):791\u2013800. https:\/\/doi.org\/10.1038\/npp.2017.171","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"7187_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/02698811221100713","volume":"36","author":"J Flameling","year":"2022","unstructured":"Flameling J, van der Does F, van Veelen N, Vermetten E (2022) Not too quick on Debunking the myth of \u2018Blue Mondays\u2019. J Psychopharmacol 36(8):1001\u20131004. https:\/\/doi.org\/10.1177\/02698811221100713","journal-title":"J Psychopharmacol"},{"issue":"2","key":"7187_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1037\/0022-3514.84.2.365","volume":"84","author":"BL Fredrickson","year":"2003","unstructured":"Fredrickson BL, Tugade MM, Waugh CE, Larkin GR (2003) What Good Are Positive Emotions in Crises? A Prospective Study of Resilience and Emotions Following the Terrorist Attacks on the United States on September 11th, 2001. J Personal Soc Psychol 84(2):365\u2013376","journal-title":"J Personal Soc Psychol"},{"issue":"1","key":"7187_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41398-026-04148-6","volume":"16","author":"M Humbert-Droz","year":"2026","unstructured":"Humbert-Droz M, Becker AM, Valenta J, Rudin D, Luethi D, Vukalovic I, Eckert A, Liechti ME, Mueller L (2026) Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: A double-blind, randomized, placebo-controlled, crossover study. Translational Psychiatry 16(1):402. https:\/\/doi.org\/10.1038\/s41398-026-04148-6","journal-title":"Translational Psychiatry"},{"issue":"2","key":"7187_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0269881106060513","volume":"20","author":"JK Huxster","year":"2006","unstructured":"Huxster JK, Pirona A, Morgan MJ (2006) The sub-acute effects of recreational ecstasy (MDMA) use: A controlled study in humans. J Psychopharmacol 20(2):281\u2013290. https:\/\/doi.org\/10.1177\/0269881106060513","journal-title":"J Psychopharmacol"},{"issue":"2","key":"7187_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0014-2999(86)90615-1","volume":"132","author":"MP Johnson","year":"1986","unstructured":"Johnson MP, Hoffman AJ, Nichols DE (1986) Effects of enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132(2):269\u2013276. https:\/\/doi.org\/10.1016\/0014-2999(86)90615-1","journal-title":"Eur J Pharmacol"},{"key":"7187_CR16","unstructured":"Koslow T SSRI and, Interactions LSD (2020) Plus Shrooms and More: Why Taking Psychedelics While on Antidepressants Could Make Treatment Ineffective. DoubleBlind Mag. https:\/\/doubleblindmag.com\/mushrooms\/how-to-take-shrooms\/how-psychedelics-contraindicate-with-ssris\/"},{"issue":"2","key":"7187_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s002130000648","volume":"154","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154(2):161\u2013168. https:\/\/doi.org\/10.1007\/s002130000648","journal-title":"Psychopharmacology"},{"issue":"6","key":"7187_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot\u2019alora G, Garas M, Paleos W, Gorman C, Nicholas I, Mithoefer C, Carlin M, Poulter S, Mithoefer B, Quevedo A, Wells S, Klaire G, van der Kolk SS, Doblin B, R (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27(6):1025\u20131033. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"issue":"10","key":"7187_CR19","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora G, van der Kolk M, Shannon B, Bogenschutz S, Gelfand M, Paleos Y, Nicholas C, Quevedo CR, Balliett S, Hamilton B, Mithoefer S, Kleiman M, Parker-Guilbert S, Tzarfaty K, Harrison K, de Boer C, Doblin A, R., Yazar-Klosinski B (2023) MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nat Med 29(10):2473\u20132480. https:\/\/doi.org\/10.1038\/s41591-023-02565-4","journal-title":"Nat Med"},{"issue":"4","key":"7187_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of \u00b1\u20093,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. J Psychopharmacol 25(4):439\u2013452. https:\/\/doi.org\/10.1177\/0269881110378371","journal-title":"J Psychopharmacol"},{"issue":"6","key":"7187_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R (2018) 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5(6):486\u2013497. https:\/\/doi.org\/10.1016\/S2215-0366(18)30135-4","journal-title":"Lancet Psychiatry"},{"key":"7187_CR22","doi-asserted-by":"publisher","unstructured":"Nayak SM, Johnson MW (2023) Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances. In A. Tasman, M. B. Riba, R. D. Alarc\u00f3n, C. A. Alfonso, S. Kanba, D. M. Ndetei, C. H. Ng, T. G. Schulze, & D. Lecic-Tosevski (Eds.), Tasman\u2019s Psychiatry (pp. 1\u201334). Springer International Publishing. https:\/\/doi.org\/10.1007\/978-3-030-42825-9_94-1","DOI":"10.1007\/978-3-030-42825-9_94-1"},{"issue":"8","key":"7187_CR23","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1523\/JNEUROSCI.08-08-02788.1988","volume":"8","author":"E O\u2019Hearn","year":"1988","unstructured":"O\u2019Hearn E, Battaglia G, Souza ED, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J Neurosci 8(8):2788\u20132803. https:\/\/doi.org\/10.1523\/JNEUROSCI.08-08-02788.1988","journal-title":"J Neurosci"},{"issue":"4","key":"7187_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hup.2318","volume":"28","author":"AC Parrott","year":"2013","unstructured":"Parrott AC (2013) Human psychobiology of MDMA or \u2018Ecstasy\u2019: An overview of 25 years of empirical research. Hum Psychopharmacology: Clin Experimental 28(4):289\u2013307. https:\/\/doi.org\/10.1002\/hup.2318","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"key":"7187_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s002130050714","volume":"139","author":"A Parrott","year":"1998","unstructured":"Parrott A, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: Before, during and after a Saturday night dance. Psychopharmacology 139:261\u2013268. https:\/\/doi.org\/10.1007\/s002130050714","journal-title":"Psychopharmacology"},{"issue":"2","key":"7187_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/0269881109102780","volume":"24","author":"A Pirona","year":"2010","unstructured":"Pirona A, Morgan M (2010) An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users. J Psychopharmacol 24(2):175\u2013185. https:\/\/doi.org\/10.1177\/0269881109102780","journal-title":"J Psychopharmacol"},{"issue":"2","key":"7187_CR27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jnr.22759","volume":"90","author":"E Puerta","year":"2012","unstructured":"Puerta E, Barros-Mi\u00f1ones L, Hervias I, Gomez-Rodriguez V, Orejana L, Pizarro N, de la Torre R, Jord\u00e1n J, Aguirre N (2012) Long-lasting neuroprotective effect of sildenafil against 3,4-methylenedioxymethamphetamine- induced 5-hydroxytryptamine deficits in the rat brain. J Neurosci Res 90(2):518\u2013528. https:\/\/doi.org\/10.1002\/jnr.22759","journal-title":"J Neurosci Res"},{"issue":"1","key":"7187_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-3565(25)22673-8","volume":"240","author":"CJ Schmidt","year":"1987","unstructured":"Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240(1):1\u20137. https:\/\/doi.org\/10.1016\/S0022-3565(25)22673-8","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"7187_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/0269881112463467","volume":"27","author":"RM Scott","year":"2013","unstructured":"Scott RM, Hides L, Allen JS, Lubman DI (2013) Subacute effects of ecstasy on mood: An exploration of associated risk factors. J Psychopharmacol 27(1):53\u201361. https:\/\/doi.org\/10.1177\/0269881112463467","journal-title":"J Psychopharmacol"},{"key":"7187_CR31","doi-asserted-by":"publisher","unstructured":"Sessa B, Higbed L, Nutt D (2019) A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Front Psychiatry 10. https:\/\/doi.org\/10.3389\/fpsyt.2019.00138","DOI":"10.3389\/fpsyt.2019.00138"},{"issue":"3","key":"7187_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/02698811211055809","volume":"36","author":"B Sessa","year":"2022","unstructured":"Sessa B, Aday JS, O\u2019Brien S, Curran HV, Measham F, Higbed L, Nutt DJ (2022) Debunking the myth of \u2018Blue Mondays\u2019: No evidence of affect drop after taking clinical MDMA. J Psychopharmacol 36(3):360\u2013367. https:\/\/doi.org\/10.1177\/02698811211055809","journal-title":"J Psychopharmacol"},{"issue":"2","key":"7187_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0014-2999(99)00728-1","volume":"385","author":"M Shankaran","year":"1999","unstructured":"Shankaran M, Yamamoto BK, Gudelsky GA (1999) Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 385(2):103\u2013110. https:\/\/doi.org\/10.1016\/S0014-2999(99)00728-1","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"7187_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/1098-2396","volume":"40","author":"M Shankaran","year":"2001","unstructured":"Shankaran M, Yamamoto BK, Gudelsky GA (2001) Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 40(1):55\u201364. https:\/\/doi.org\/10.1002\/1098-2396:1%3C55::AID-SYN1026%3E3.0.CO;2-O","journal-title":"Synapse"},{"issue":"11","key":"7187_CR34","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.5664\/jcsm.7478","volume":"14","author":"E Snyder","year":"2018","unstructured":"Snyder E, Cai B, DeMuro C, Morrison MF, Ball W (2018) A New Single-Item Sleep Quality Scale: Results of Psychometric Evaluation in Patients With Chronic Primary Insomnia and Depression. J Clin Sleep Medicine: JCSM : Official Publication Am Acad Sleep Med 14(11):1849\u20131857. https:\/\/doi.org\/10.5664\/jcsm.7478","journal-title":"J Clin Sleep Medicine: JCSM : Official Publication Am Acad Sleep Med"},{"issue":"4","key":"7187_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s11011-013-9423-1","volume":"28","author":"S Soleimani Asl","year":"2013","unstructured":"Soleimani Asl S, Mousavizedeh K, Pourheydar B, Soleimani M, Rahbar E, Mehdizadeh M (2013) Protective effects of N-acetylcysteine on 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in male Sprague\u2013Dawley rats. Metab Brain Dis 28(4):677\u2013686. https:\/\/doi.org\/10.1007\/s11011-013-9423-1","journal-title":"Metab Brain Dis"},{"issue":"7","key":"7187_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hup.529","volume":"18","author":"SL Verheyden","year":"2003","unstructured":"Verheyden SL, Henry JA, Curran HV (2003) Acute, sub-acute and long-term subjective consequences of \u2018ecstasy\u2019 (MDMA) consumption in 430 regular users. Hum Psychopharmacology: Clin Experimental 18(7):507\u2013517. https:\/\/doi.org\/10.1002\/hup.529","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"issue":"5","key":"7187_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol 31(5):576\u2013588. https:\/\/doi.org\/10.1177\/0269881117691569","journal-title":"J Psychopharmacol"},{"issue":"4","key":"7187_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.npp.1395197","volume":"19","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (Ecstasy) in MDMA-Na\u0131\u0308ve Healthy Volunteers. Neuropsychopharmacology 19(4):241\u2013251","journal-title":"Neuropsychopharmacology"},{"key":"7187_CR39","unstructured":"Zelfand E (2023) Supplements to Reduce Side Effects of MDMA. https:\/\/psychedelic.support\/resources\/supplements-to-reduce-side-effects-mdma\/"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07187-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:05:05Z","timestamp":1792224305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07187-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":39,"alternative-id":["7187"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07187-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SPG reports a relationship with Palo Santo that includes: consulting or advisory. DBY has received research support from the NIH, the Gracias Family Foundation, the Heffter Research Institute, and philanthropic donors to the Johns Hopkins Center for Psychedelic and Consciousness Research. He co-directs the Hub at Oxford for Psychedelic Ethics (HOPE), which has received a small anonymous donation to support travel for underrepresented workshop participants; DBY does not personally receive financial support for this role. DBY has received consulting a fee from Soneira and educational speaking fees from the Integrative Psychiatry Institute. SMN reports a relationship with Resilient Pharmaceuticals that includes: consulting or advisory.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}